The Academy commends UnitedHealthcare (UHC) for acting quickly to clarify its policy regarding the use of two biosimilars untested for ophthalmic/intravitreal use as alternatives to the sight-saving drug Avastin. UHC removed the drugs, Mvasi and Zirabev.
The Philippines’ 2019 Universal Health Care Act and regulatory tax reforms open new avenues for the Indian pharmaceutical industry, according to new research.